127 related articles for article (PubMed ID: 3332142)
1. Allogeneic and syngeneic marrow transplantation following high dose dimethylbusulfan, cyclophosphamide and total body irradiation.
Kanfer EJ; Buckner CD; Fefer A; Storb R; Appelbaum FR; Hill RS; Amos D; Doney KC; Clift RA; Shulman HM
Bone Marrow Transplant; 1987 Apr; 1(4):339-46. PubMed ID: 3332142
[TBL] [Abstract][Full Text] [Related]
2. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
3. Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.
Petersen FB; Buckner CD; Appelbaum FR; Clift RA; Sanders JE; Bensinger WI; Storb R; Witherspoon RP; Sullivan KM; Bearman SI
Bone Marrow Transplant; 1989 Nov; 4(6):617-23. PubMed ID: 2684307
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
Jillella AP; Doria R; Khan K; Zelterman D; Ahmad YH; Smith BR; Holmes W; Becker P; Roberts KB; Rappeport JM
Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary complications of bone marrow transplantation: a comparison of total body irradiation and cyclophosphamide to busulfan and cyclophosphamide.
Hartsell WF; Czyzewski EA; Ghalie R; Kaizer H
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):69-73. PubMed ID: 7536723
[TBL] [Abstract][Full Text] [Related]
6. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
7. Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy.
Van der Jagt RH; Appelbaum FR; Petersen FB; Bigelow CL; Fisher LD; Schoch GH; Buckner CD; Sanders JE; Storb R; Sullivan KM
Bone Marrow Transplant; 1991 Sep; 8(3):211-5. PubMed ID: 1958901
[TBL] [Abstract][Full Text] [Related]
8. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
Vaughan WP; Dennison JD; Reed EC; Klassen L; McGuire TR; Sanger WG; Kumar PP; Warkentin PI; Gordon BG; Bierman PJ
Bone Marrow Transplant; 1991 Dec; 8(6):489-95. PubMed ID: 1790429
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group.
Ringdén O; Remberger M; Ruutu T; Nikoskelainen J; Volin L; Vindeløv L; Parkkali T; Lenhoff S; Sallerfors B; Mellander L; Ljungman P; Jacobsen N
Blood; 1999 Apr; 93(7):2196-201. PubMed ID: 10090927
[TBL] [Abstract][Full Text] [Related]
10. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
Demirer T; Buckner CD; Appelbaum FR; Bensinger WI; Sanders J; Lambert K; Clift R; Fefer A; Storb R; Slattery JT
Bone Marrow Transplant; 1996 Apr; 17(4):491-5. PubMed ID: 8722344
[TBL] [Abstract][Full Text] [Related]
11. The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation.
Morgan M; Dodds A; Atkinson K; Szer J; Downs K; Biggs J
Br J Haematol; 1991 Apr; 77(4):529-34. PubMed ID: 2025579
[TBL] [Abstract][Full Text] [Related]
12. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
[TBL] [Abstract][Full Text] [Related]
13. Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation.
Sanders JE; Buckner CD; Clift RA; Fefer A; McGuffin R; Storb R; Appelbaum F; Bensinger W; Beatty P; Doney K
Bone Marrow Transplant; 1988 Jan; 3(1):11-9. PubMed ID: 3048466
[TBL] [Abstract][Full Text] [Related]
14. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
Przepiorka D; Khouri I; Thall P; Mehra R; Lee MS; Ippoliti C; Giralt S; Gajewski J; van Besien K; Andersson B; Körbling M; Deisseroth AB; Champlin R
Bone Marrow Transplant; 1999 May; 23(10):977-81. PubMed ID: 10373061
[TBL] [Abstract][Full Text] [Related]
15. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
[TBL] [Abstract][Full Text] [Related]
16. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
Spitzer TR; Cottler-Fox M; Torrisi J; Cahill R; Greenspan A; Lynch M; Deeg HJ
Bone Marrow Transplant; 1989 Sep; 4(5):559-65. PubMed ID: 2676044
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
[TBL] [Abstract][Full Text] [Related]
18. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide.
Santos GW; Tutschka PJ; Brookmeyer R; Saral R; Beschorner WE; Bias WB; Braine HG; Burns WH; Elfenbein GJ; Kaizer H
N Engl J Med; 1983 Dec; 309(22):1347-53. PubMed ID: 6355849
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group.
Ringdén O; Ruutu T; Remberger M; Nikoskelainen J; Volin L; Vindeløv L; Parkkali T; Lenhoff S; Sallerfors B; Ljungman P
Blood; 1994 May; 83(9):2723-30. PubMed ID: 8167351
[TBL] [Abstract][Full Text] [Related]
20. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
Wu DP; Milpied N; Moreau P; Mechinaud-Lacroix F; Mahe B; Le Tortorec S; Rapp MJ; Bourdin S; Mahe JM; Harousseau JL
Bone Marrow Transplant; 1994 Nov; 14(5):751-7. PubMed ID: 7889008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
